Article

Results: CATT at 1 year

A head-to-head comparison of ranibizumab (Lucentis, Genentech) and bevacizumab (Avastin, Genentech) in the Comparison of Age-related Macular Degeneration Treatments Trials indicated that at the 1-year time point, both drugs were clinically equivalent for treating the disease, said Daniel Martin, MD

Orlando-A head-to-head comparison of ranibizumab (Lucentis, Genentech) and bevacizumab (Avastin, Genentech) in the Comparison of Age-related Macular Degeneration (AMD) Treatments Trials (CATT) indicated that at the 1-year time point, both drugs were clinically equivalent for treating the disease, said Daniel Martin, MD.

The study included four treatment arms: two using monthly dosing and two using as-needed dosing, with a total of 1,208 patients.

Dr. Martin, speaking on behalf of the CATT study group, presented the highlights of the study. The letter increases in visual acuity were similar in the monthly dosing groups, with ranibizumab achieving a mean of +8.5 letters and bevacizumab a mean of +8 letters; in the as-needed dosing groups, ranibizumab achieved a mean of +6.8 letters and bevacizumab a mean of +5.9 letters. The study results were inconclusive when comparing ranibizumab as needed with bevacizumab as needed.

“The visual acuity analysis at 1 year showed no significant difference between the two drugs,” Dr. Martin said.

There were similar rates of death, heart attack, and stroke between the two drugs. There was a difference in the number of total serious adverse events that occurred, which he described as “perplexing.”

“There was a marginally significant difference in the serious adverse events between the drugs, with bevacizumab associated with higher rates of hospitalizations compared with ranibizumab (24% versus 19%),” Dr. Martin said. “This difference may be due to chance, imbalance at baseline, or risk. The 2-year results may tell.”

The most serious adverse event was endophthalmitis (n = 6), which occurred in the as-needed groups.

For more articles in this issue of Ophthalmology Times Conference Brief click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.